Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies.

Ueberberg S, Jütte H, Uhl W, Schmidt W, Nauck M, Montanya E, Tannapfel A, Meier J.

Diabetes Obes Metab. 2016 Dec;18(12):1253-1262. doi: 10.1111/dom.12766. Epub 2016 Sep 26. Erratum in: Diabetes Obes Metab. 2017 Feb;19(2):306.

PMID:
27545110
2.

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors.

Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC.

Diabetes. 2013 Jul;62(7):2595-604. doi: 10.2337/db12-1686. Epub 2013 Mar 22.

3.

Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.

Kirk RK, Pyke C, von Herrath MG, Hasselby JP, Pedersen L, Mortensen PG, Knudsen LB, Coppieters K.

Diabetes Obes Metab. 2017 May;19(5):705-712. doi: 10.1111/dom.12879. Epub 2017 Mar 10.

PMID:
28094469
4.

Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.

Siddiqui NI.

Mymensingh Med J. 2009 Jan;18(1):113-24. Review.

PMID:
19182763
5.

Incretin Therapies Do Not Expand β-Cell Mass or Alter Pancreatic Histology in Young Male Mice.

Cox AR, Lam CJ, Rankin MM, Rios JS, Chavez J, Bonnyman CW, King KB, Wells RA, Anthony D, Tu JX, Kim JJ, Li C, Kushner JA.

Endocrinology. 2017 Jun 1;158(6):1701-1714. doi: 10.1210/en.2017-00027.

6.

Incretin-based therapies in type 2 diabetes: a review of clinical results.

Bosi E, Lucotti P, Setola E, Monti L, Piatti PM.

Diabetes Res Clin Pract. 2008 Dec 15;82 Suppl 2:S102-7. doi: 10.1016/j.diabres.2008.10.003. Epub 2008 Nov 20. Review.

PMID:
19022515
7.

Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.

Bourdel-Marchasson I, Schweizer A, Dejager S.

Hosp Pract (1995). 2011 Feb;39(1):7-21. doi: 10.3810/hp.2011.02.369. Review.

PMID:
21441754
8.

Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.

Campbell RK, Cobble ME, Reid TS, Shomali ME.

J Fam Pract. 2010 Sep;59(9 Suppl 1):S5-9.

PMID:
20824239
9.

Incretins: their physiology and application in the treatment of diabetes mellitus.

Tasyurek HM, Altunbas HA, Balci MK, Sanlioglu S.

Diabetes Metab Res Rev. 2014 Jul;30(5):354-71. doi: 10.1002/dmrr.2501. Review.

PMID:
24989141
10.

[The value of incretin based therapies].

Gallwitz B.

Dtsch Med Wochenschr. 2009 May;134(20):1062-6. doi: 10.1055/s-0029-1222570. Epub 2009 May 6. Review. German. No abstract available.

PMID:
19421931
11.
12.

Decreased α-cell mass and early structural alterations of the exocrine pancreas in patients with type 1 diabetes: An analysis based on the nPOD repository.

Bonnet-Serrano F, Diedisheim M, Mallone R, Larger E.

PLoS One. 2018 Jan 19;13(1):e0191528. doi: 10.1371/journal.pone.0191528. eCollection 2018.

13.

Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.

Campbell RK, Cobble ME, Reid TS, Shomali ME.

J Fam Pract. 2010 Sep;59(9 Suppl 1):S10-9.

PMID:
20824235
14.

Automated recognition and quantification of pancreatic islets in Zucker diabetic fatty rats treated with exendin-4.

Kakimoto T, Kimata H, Iwasaki S, Fukunari A, Utsumi H.

J Endocrinol. 2013 Jan 2;216(1):13-20. doi: 10.1530/JOE-12-0456. Print 2013 Jan.

PMID:
23092878
15.

Localization of dipeptidyl peptidase-4 (CD26) to human pancreatic ducts and islet alpha cells.

Augstein P, Naselli G, Loudovaris T, Hawthorne WJ, Campbell P, Bandala-Sanchez E, Rogers K, Heinke P, Thomas HE, Kay TW, Harrison LC.

Diabetes Res Clin Pract. 2015 Dec;110(3):291-300. doi: 10.1016/j.diabres.2015.10.010. Epub 2015 Oct 26.

PMID:
26515908
16.

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

Jellinger PS.

Postgrad Med. 2011 Jan;123(1):53-65. doi: 10.3810/pgm.2011.01.2245. Review.

PMID:
21293084
17.

Autophagy deficiency in β cells blunts incretin-induced suppression of glucagon release from α cells.

Kim MJ, Choi OK, Chae KS, Lee H, Chung SS, Ham DS, Kim JW, Yoon KH, Park KS, Jung HS.

Islets. 2015;7(5):e1129096. doi: 10.1080/19382014.2015.1129096.

18.

Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.

Campbell RK, Cobble ME, Reid TS, Shomali ME.

J Fam Pract. 2010 Sep;59(9 Suppl 1):S20-7.

PMID:
20824236
19.

Dysfunction of the pancreas in healthy smoking persons and patients with chronic pancreatitis.

Milnerowicz H, Sliwinska-Mosson M, Rabczyński J, Nowak M, Milnerowicz S.

Pancreas. 2007 Jan;34(1):46-54.

PMID:
17198182
20.

Supplemental Content

Support Center